Arena Faces New FDA Worries Over Weight-Loss Drug

Law360, New York (May 8, 2012, 7:48 PM EDT) -- U.S. Food and Drug Administration drug reviewers said Tuesday that Arena Pharmaceuticals had eased concerns about potential cancer risks associated with its obesity drug lorcaserin, but said a high risk of heart valve disease could not be ruled out.

The reviewers provided the update in a 246-page briefing document ahead of a FDA advisory committee meeting Thursday to discuss the safety and efficacy of lorcaserin, a drug to help obese patients lose weight.

Lorcaserin was earlier linked to mammary gland tumors in both sexes in a...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.